CRBP · Corbus Pharmaceuticals Holdings, Inc.

Track CRBP — free

$11.25 -0.03 (-0.27%)

Russell 2000 member Rebalance outlook locked

Market Cap

$206.37M

19.34M

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 114 metrics

Revenue (TTM)

Trailing 12 months

Net income (TTM)

−$101.90M

Trailing 12 months

Revenue growth YoY

-100.0%

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+58.6%

Year over year · more shares

Price change (1Y)

+20.4%

Trailing year

Short interest

11.1%

Latest settlement · 6.0 days to cover

View all 114 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Strong Buy Momentum Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.67

Technical

price trend

Strong Buy

50 / 200-day cross Golden cross

Price vs 200-day avg +22%

above

Price vs 50-day avg +18%

above

RSI (14) 67

neutral

MACD trend Positive

52-week position 33%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return +20%

trailing

6-month return +8%

trailing

YTD return +39%

this year

Relative strength −4%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) Golden cross

50d $10 › 200d $9 — 50d above 200d

Institutional flow Distributing

-1% holders QoQ · +24 funds added

Insider flow Accumulating

Net +$25.0K over 90 days · 0% sells

Short interest Falling

11.10% of float · ▼ -6.6% MoM · 6.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

106 holders — mid 3-yr range

Squeeze score 67

elevated · 0–100

Fundamentals

Weak

Revenue growth +98%

Y/Y

EPS growth −60%

Y/Y

Free cash flow $-64.5M

Balance sheet $4.2M

net debt

Quant / Vol

risk profile

Very High

Volatility 79%

annualized · 1-yr

Max drawdown −62%

past year

ATR 5.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 3 · 4

50 / 200-day cross

Golden cross Bullish

Price vs 200-day avg

+22% Bullish

Price vs 50-day avg

+18% Bullish

RSI (14)

67 Neutral

MACD trend

Positive Bullish

52-week position

33% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) Golden cross

50d $10 › 200d $9 — 50d above 200d

Institutional flow Distributing

-1% holders QoQ · +24 funds added

Insider flow Accumulating

Net +$25.0K over 90 days · 0% sells

Short interest Falling

11.10% of float · ▼ -6.6% MoM · 6.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

106 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $7 Now $11 · 33% Range high $19

vs 200-day avg +22% vs 50-day avg +18% 50-day above 200-day golden cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CRBP Corbus Pharmaceuticals Holdings, Inc. this stock	$206.37M	+38.6%	+97.6%	—	11.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$137.30B	+20.8%	+46.2%	31.6	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$84.82B	+6.7%	+20.8%	20.4	2.3%
ARGX Argenx SE	$64.16B	+22.3%	—	—	1.9%
MRNA Moderna, Inc.	$61.59B	+423.1%	+4.3%	—	13.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

106

% held: 80.1%
Net QoQ: +2.3M sh
Top holder: Cormorant Asset Managemen…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

2.1M

Days to cover: 6.0d
Change: -151.7K sh

View

Short Volume

Short vol %

63%

As of: Sep 1, 2026

Short Total

View

Fails to Deliver

FTD shares

201

Value: $1.9K
As of: Aug 12, 2026

View

Off-Exchange

Off-exchange %

39.6%

Week of: Jul 27, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$25.0K

Buyers / Sellers: 1 / 0

Buyers Sellers

View

Financials

Revenue (FY)

Net income (FY): $-78.5M
EPS diluted: $-5.90

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 6, 2026
This year: 18

View

Proposed Sales

Value

$171.4K

Shares: 17.0K
Filed: Aug 7, 2026

View

Earnings & Events

Earnings Calls

Last call

Jun 4, 2026

View

Performance

Raw-price comparisons begin at the captured split on Feb 14, 2023; windows that need an earlier baseline remain unavailable.

	5D	20D	120D	MTD	YTD
CRBP	-0.3%	+20.0%	+8.2%	+3.4%	+38.6%
SPY	-0.5%	-1.2%	+12.6%	-0.7%	+11.7%
vs SPY	+0.3%	+21.2%	-4.5%	+4.1%	+26.9%

Key facts CIK 1595097 CUSIP 21833P301 13F (30d) 90 filings 89 filers Visit website Investor relations

CRBP · Corbus Pharmaceuticals Holdings, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Versus peers

At a glance

Performance